cactinomycin: a mixture of dactinomycin, actinomycin C2, and actinomycin C3 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3084037 |
| SCHEMBL ID | 1650567 |
| MeSH ID | M0095292 |
| Synonym |
|---|
| 0occ969v50 , |
| cactinomycine |
| unii-0occ969v50 |
| cactinomycinum |
| cactinomicina |
| nsc 18268 |
| actinomycin d, 2(sup a)-d-alloisoleucine-2(sup b)-d-alloisoleucine-, mixt. with actinomycin d and 2(sup a)-d-alloisoleucineactinomycin d |
| cactinomycin [usan:inn] |
| sanamicia |
| cactinomycine [inn-french] |
| cactinomicina [inn-spanish] |
| einecs 232-485-1 |
| h.b.f. 386 |
| cactinomycinum [inn-latin] |
| 8052-16-2 |
| sanamycin |
| actinochrysin |
| nsc-18268 |
| actinomycin c |
| cactinomycin |
| 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa |
| SCHEMBL1650567 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Prostaglandins (PGs) have been shown to cytoprotect various tissue types against the toxic effects of many chemicals." | ( The cytoprotective properties of prostaglandin E2 against the toxic effects of actinomycin C on embryonic neural retina cells. Dymond, JB; Kalmus, GW, 1992) | 0.28 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 66 (74.16) | 18.7374 |
| 1990's | 10 (11.24) | 18.2507 |
| 2000's | 9 (10.11) | 29.6817 |
| 2010's | 4 (4.49) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (0.99%) | 5.53% |
| Reviews | 1 (0.99%) | 6.00% |
| Case Studies | 2 (1.98%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 97 (96.04%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma [NCT00075582] | Phase 3 | 390 participants (Actual) | Interventional | 2004-09-04 | Completed | ||
| "A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus Pulsed Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia" [NCT00003702] | Phase 3 | 240 participants (Actual) | Interventional | 1999-06-30 | Completed | ||
| Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor [NCT00352534] | Phase 3 | 808 participants (Actual) | Interventional | 2006-10-30 | Active, not recruiting | ||
| Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors [NCT00379340] | Phase 3 | 395 participants (Actual) | Interventional | 2007-02-26 | Active, not recruiting | ||
| Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS) [NCT00354835] | Phase 3 | 481 participants (Actual) | Interventional | 2006-12-26 | Completed | ||
| A Prospective Phase 3 Study of Patients With Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma [NCT05304585] | Phase 3 | 205 participants (Anticipated) | Interventional | 2022-08-04 | Recruiting | ||
| A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance i [NCT04994132] | Phase 3 | 118 participants (Anticipated) | Interventional | 2021-09-14 | Recruiting | ||
| A Phase I/II Study of Isolated Limb Infusion and Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma [NCT01531244] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2014-12-31 | Withdrawn | ||
| Treatment for Patients With Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor [NCT00945009] | Phase 3 | 249 participants (Actual) | Interventional | 2009-07-13 | Active, not recruiting | ||
| Randomized Study of Vincristine, Actinomycin-D, and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine, Topotecan and Cyclophosphamide for Patients With Intermediate Risk Rhabdomyosarcoma [NCT00003958] | Phase 3 | 702 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with a maximum grade of 3 or higher during the treatment period. (NCT00003702)
Timeframe: Prior to study entry, weekly during treatment, up to 12 months after normal titer, an average of 7 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1: Methotrexate 30 mg/m2 IM Weekly | 14 |
| Arm 2: Dactinomycin 1.25 mg/m2 IV Push Every 2 Weeks | 20 |
Number of patients with a decline in hCG on day 1 of treatment relative to the level at enrollment. A decline is defined as a decrease by 1 or more units between enrollment and treatment start. (NCT00003702)
Timeframe: Prior to study entry and on Day 1 of treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Enrolled Participants | 72 |
Primary outcome is measured as a difference in proportion responding between treatment arms and evaluated using a chi square test. A complete response was defined as a normal hCG sustained over four weekly measurements. (NCT00003702)
Timeframe: Endpoint was assessed by hCG measurements taken weekly, once normal, treatment was bi-weekly, then monthly, up to 12 months.
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Complete/Cure | Non-response | Inevaluable | |
| Arm 1: Methotrexate 30 mg/m2 IM Weekly | 57 | 48 | 2 |
| Arm 2: Dactinomycin 1.25 mg/m2 IV Push Every 2 Weeks | 76 | 29 | 4 |
The local failure rate will be estimated using cumulative incidence curves for Group III patients who received reduced doses of radiation therapy after second look surgical resection. (NCT00075582)
Timeframe: From enrollment up to 20 weeks
| Intervention | Estimated percentage of participants (Number) |
|---|---|
| Regimen II (Stage I Group III Nonorbit or Stage III Group I/II | 0 |
The local failure rate will be estimated using cumulative incidence curves. (NCT00075582)
Timeframe: From enrollment up to 5 years
| Intervention | stimated percentage of participants (Number) |
|---|---|
| Regimen I (Chemotherapy, Radiotherapy) | 0.081 |
| Regimen II (Chemotherapy, Radiotherapy, Surgery) | 0.115 |
The decision to perform second-look surgery should be based on the physical examination and imaging studies at Week 12 and should only be considered if a reasonable functional and cosmetic result is anticipated. (NCT00075582)
Timeframe: At 13 weeks after induction
| Intervention | percentage of participants (Number) |
|---|---|
| Regimen II (Stage I Group III Nonorbit or Stage III Group I/II | 0.49 |
Kaplan Meier estimate of failure free survival at 5 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first. (NCT00075582)
Timeframe: From enrollment up to 5 years
| Intervention | Estimated percentage of participants (Number) |
|---|---|
| Regimen I (Chemotherapy, Radiotherapy) | 87 |
| Regimen II (Chemotherapy, Radiotherapy, Surgery) | 67 |
Kaplan Meier estimate of failure free survival at 5 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first. (NCT00075582)
Timeframe: From enrollment up to 5 years
| Intervention | Estimated percentage of participants (Number) |
|---|---|
| Regimen II (Chemotherapy, Radiotherapy, Surgery) | 67 |
Kaplan Meier estimate of failure free survival at 5 years, where failure free survival is defined as the time to relapse, progression, second malignancy, and death whichever occurs first. (NCT00075582)
Timeframe: From enrollment up to 5 years
| Intervention | Estimated percentage of participants (Number) |
|---|---|
| Regimen I (Chemotherapy, Radiotherapy) | 90 |
Probability of no relapse, secondary malignancy, or death after 4 year in the study. (NCT00352534)
Timeframe: 4 years
| Intervention | Probability (Number) |
|---|---|
| Very Low Risk | 0.88 |
| Standard Risk, Stage I or II, With LOH | 0.87 |
| Standard Risk, Stage III | 0.88 |
Number of contralateral kidney lesions during follow-up. (NCT00352534)
Timeframe: During follow-up
| Intervention | Lesions (Number) |
|---|---|
| Very Low Risk | 1 |
Number of renal failures defined as requiring dialysis or renal transplant as determined by low GFR during follow-up (NCT00352534)
Timeframe: During follow-up
| Intervention | Incidents (Number) |
|---|---|
| Very Low Risk | 0 |
Probability of being alive after 4 years in the study. (NCT00352534)
Timeframe: 4 years
| Intervention | Probability (Number) |
|---|---|
| Very Low Risk | 1.00 |
| Standard Risk, Stage I or II, With LOH | 1.00 |
| Standard Risk, Stage III | 0.97 |
Compare 4-year OS using eligible participants only to the historical rate of 0.70 with IRSI-V. The 4-year OS is probability of being alive after 4 years in the study. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.70. (NCT00354835)
Timeframe: 4 years
| Intervention | Probability (Number) |
|---|---|
| Vincristine, Dactinomycin, Cyclophosphamide (VAC) | 0.7293 |
Proportion of patients with complete or partial response. Complete Response (CR): Complete disappearance of the tumor confirmed at > 4 weeks; Partial Response (PR): At least 64% decrease in volume compared to the baseline; Overall Response (OR) = CR + PR. (NCT00354835)
Timeframe: Reporting Period 1 (Weeks 1 - 15)
| Intervention | Proportion (Number) |
|---|---|
| Vincristine, Dactinomycin, Cyclophosphamide (VAC) | 0.6667 |
| VAC Alternating With Vincristine, Irinotecan (VI) | 0.6726 |
The toxicity rates will be estimated for each phase and course of treatment, and will be compared to the fixed rates under D9803 using one-sided lower confidence intervals for a single proportion without adjustment for multiple comparisons. (NCT00354835)
Timeframe: Up to 43 weeks
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Anemia | Febrile Neutropenia | Nausea or Hepatopathy | Platelet Count Decreased | Vomiting | |
| VAC (Weeks 1-15) | 58 | 30 | 6 | 27 | 9 |
| VAC (Weeks 31 - 43) | 54 | 17 | 1 | 63 | 2 |
Severe and undesirable adverse event is considered as grade 3; Life-threatening or disabling adverse event is grade 4. Grade 4 is worse than grade 3. (NCT00354835)
Timeframe: Weeks 4-9 (the first exposure to VI)
| Intervention | Counts (Number) | |
|---|---|---|
| Neutropenia, with or without Fever | Diarrhea | |
| UGT1A1 Genotype 6/6 | 16 | 5 |
| UGT1A1 Genotype 6/7 | 22 | 14 |
| UGT1A1 Genotype 7/7 | 4 | 5 |
4-year EFS (probability of no relapse, secondary malignancy, or death after 4 years in the study) (NCT00354835)
Timeframe: 4 years
| Intervention | Probability (Number) |
|---|---|
| % Change in SUVmax From Baseline to Week 15 < 40% | 0.6667 |
| % Change in SUVmax From Baseline to Week 15 >= 40% | 0.5686 |
4-year EFS (probability of no relapse, secondary malignancy, or death after 4 years in the study). (NCT00354835)
Timeframe: 4 years
| Intervention | Probability (Number) |
|---|---|
| % Change in SUVmax From Baseline to Week 4 < 40% | 0.2857 |
| % Change in SUVmax From Baseline to Week 4 >= 40% | 0.6364 |
Probability of no relapse, secondary malignancy, or death after 4 year in the study (NCT00354835)
Timeframe: 4 years
| Intervention | Probability (Number) |
|---|---|
| Vincristine, Dactinomycin, Cyclophosphamide (VAC) | 0.6255 |
| VAC Alternating With Vincristine, Irinotecan (VI) | 0.5874 |
(NCT00354835)
Timeframe: 4 years
| Intervention | Probability (Number) |
|---|---|
| PAX3 | 0.51 |
| PAX7 | 0.66 |
Compare 4-year EFS using eligible participants only to the historical rate of 0.65 with IRSI-V. The 4-year EFS is probability of no relapse, secondary malignancy, or death after 4 years in the study. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.65. (NCT00354835)
Timeframe: 4 years
| Intervention | Probability (Number) |
|---|---|
| Vincristine, Dactinomycin, Cyclophosphamide (VAC) | 0.6255 |
Number of patients with a summary score greater than 8.5 (NCT00354835)
Timeframe: 3-6 years after enrollment
| Intervention | Participant (Number) |
|---|---|
| Vincristine, Dactinomycin, Cyclophosphamide (VAC) | 2 |
| VAC Alternating With Vincristine, Irinotecan (VI) | 1 |
Grade 3 or 4 nausea, diarrhea, dehydration, radiation dermatitis, mucositis due to radiation. Severe and undesirable adverse event is considered as grade 3; Life-threatening or disabling adverse event is grade 4. Grade 4 is worse than grade 3. (NCT00354835)
Timeframe: Up to 15 weeks
| Intervention | Probability (Number) |
|---|---|
| Vincristine, Dactinomycin, Cyclophosphamide (VAC) | 0.2072 |
| VAC Alternating With Vincristine, Irinotecan (VI) | 0.3673 |
Compare 2-year local failure rate to the historical rate of 0.13 with IRSI-V. The Delayed (Week 10) Radiotherapy is from IRSI-V, and the number of participants of IRSI-V is unknown, but we have the rate of 0.13. (NCT00354835)
Timeframe: 2 years
| Intervention | Proportion of participants (Number) |
|---|---|
| Vincristine, Dactinomycin, Cyclophosphamide (VAC) | 0.1757 |
Probability of being alive after 4 years in the study. (NCT00354835)
Timeframe: 4 years
| Intervention | Probability (Number) |
|---|---|
| Vincristine, Dactinomycin, Cyclophosphamide (VAC) | 0.7293 |
| VAC Alternating With Vincristine, Irinotecan (VI) | 0.7223 |
Probability of no relapse, secondary malignancy, or death after 4 year in the study. (NCT00379340)
Timeframe: At 4 years
| Intervention | Probability of EFS at 4 years (Number) |
|---|---|
| Stage IV and Slow Incomplete Response (SIR) of Lung Metastases | 0.89 |
Probability of no relapse, secondary malignancy, or death after 4 year in the study. (NCT00379340)
Timeframe: At 4 years
| Intervention | Probability (Number) |
|---|---|
| Lung Mets <= 1cm | 0.88 |
| Lung Mets > 1cm | 0.82 |
Probability of no relapse, secondary malignancy, or death after 4 year in the study (NCT00379340)
Timeframe: At 4 years
| Intervention | Probability of EFS at 4 years (Number) |
|---|---|
| Stage III/IV With LOH 1p and 16q Treated With Regimen M | 0.90 |
| Stage IV With Non-lung Disease Treated With Regimen M | 0.73 |
Probability of no relapse, secondary malignancy, or death after 4 year in the study. (NCT00379340)
Timeframe: 4 years
| Intervention | Probability (Number) |
|---|---|
| Stage IV and Rapid Complete Response (RCR) of Lung Metastases | 0.79 |
Probability of no relapse, secondary malignancy, or death whichever occurs first (NCT00945009)
Timeframe: 4 years from study enrollment
| Intervention | Probability (Mean) |
|---|---|
| Arm 1 (Bilateral Wilms Tumors) | 0.82 |
Prevention of complete removal of at least one kidney in 50% of patients with bilateral Wilms tumor (BWT). (NCT00945009)
Timeframe: 12 weeks from study entry
| Intervention | Percentage of patients (Number) |
|---|---|
| Arm 1 (Bilateral Wilms Tumors) | 39 |
To evaluate the efficacy of chemotherapy in preserving renal units in children with diffuse hyperplastic perilobar nephroblastomatosis (DHPLN) and preventing Wilms tumor development. (NCT00945009)
Timeframe: 12 weeks from the study entry
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 3 (DHPLN) | 7 |
Percentage of patients who experienced partial nephrectomy in lieu of nephrectomy in 25% of children with unilateral tumors and aniridia, Beckwith-Wiedemann syndrome (BWS), hemihypertrophy or other overgrowth syndromes, by using prenephrectomy 2-drug chemotherapy induction with vincristine and dactinomycin. (NCT00945009)
Timeframe: 12 weeks from study entry
| Intervention | percentage of patients (Number) |
|---|---|
| Arm 2 (Unilateral High Risk Tumors Bilaterally Predisposed) | 57 |
Percentage of Bilateral Wilms Tumor (BWT) patients who undergo definitive surgery by week 12 after initiation of chemotherapy. (NCT00945009)
Timeframe: 12 weeks from study entry
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1 (Bilateral Wilms Tumors) | 85 |
| Substance | Relationship Strength | Studies | Trials | Classes | Roles |
|---|---|---|---|---|---|
| ammonium hydroxide azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2. | 1.93 | 1 | 0 | azane; gas molecular entity; mononuclear parent hydride | EC 3.5.1.4 (amidase) inhibitor; metabolite; mouse metabolite; neurotoxin; NMR chemical shift reference compound; nucleophilic reagent; refrigerant |
| amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity. | 2.4 | 2 | 0 | acridines; aromatic ether; sulfonamide | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor |
| azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS. | 2.34 | 2 | 0 | aryl sulfide; C-nitro compound; imidazoles; thiopurine | antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug |
| ellipticine ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11. | 2.4 | 2 | 0 | indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene | antineoplastic agent; plant metabolite |
| ethidium Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA. | 2.92 | 4 | 0 | phenanthridines | fluorochrome; intercalator |
| 1-methyl-3-isobutylxanthine 1-Methyl-3-isobutylxanthine: A potent cyclic nucleotide phosphodiesterase inhibitor; due to this action, the compound increases cyclic AMP and cyclic GMP in tissue and thereby activates CYCLIC NUCLEOTIDE-REGULATED PROTEIN KINASES. 3-isobutyl-1-methylxanthine : An oxopurine that is xanthine which is substituted at positions 1 and 3 by methyl and isobutyl groups, respectively. | 1.96 | 1 | 0 | 3-isobutyl-1-methylxanthine | |
| p-fluorophenylalanine p-Fluorophenylalanine: 3-(p-Fluorophenyl)-alanine.. 4-fluorophenylalanine : A phenylalanine derivative in which the hydrogen at position 4 on the benzene ring is replaced by a fluoro group. | 1.96 | 1 | 0 | fluoroamino acid; monofluorobenzenes; non-proteinogenic alpha-amino acid; phenylalanine derivative | |
| prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively. | 1.96 | 1 | 0 | aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines | alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor |
| thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed). | 1.93 | 1 | 0 | aziridines | |
| mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae. | 1.93 | 1 | 0 | mitomycin | alkylating agent; antineoplastic agent |
| floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract. | 2.02 | 1 | 0 | nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside | antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent |
| prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid. | 1.94 | 1 | 0 | 11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug |
| adenosine monophosphate Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. | 2.13 | 1 | 0 | adenosine 5'-phosphate; purine ribonucleoside 5'-monophosphate | adenosine A1 receptor agonist; cofactor; EC 3.1.3.1 (alkaline phosphatase) inhibitor; EC 3.1.3.11 (fructose-bisphosphatase) inhibitor; fundamental metabolite; micronutrient; nutraceutical |
| colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions. | 1.94 | 1 | 0 | alkaloid; colchicine | anti-inflammatory agent; gout suppressant; mutagen |
| cycloheximide Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus. | 4.16 | 6 | 0 | antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol | anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor |
| cordycepin [no description available] | 2.02 | 1 | 0 | 3'-deoxyribonucleoside; adenosines | antimetabolite; nucleoside antibiotic |
| rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds. | 2.13 | 1 | 0 | organic heteropentacyclic compound; rotenones | antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin |
| azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia. | 1.96 | 1 | 0 | N-glycosyl-1,3,5-triazine; nucleoside analogue | antineoplastic agent |
| camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source | 2.69 | 3 | 0 | delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol | antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite |
| daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola. | 3.11 | 5 | 0 | aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones | antineoplastic agent; bacterial metabolite |
| triamcinolone Triamcinolone: A glucocorticoid given, as the free alcohol or in esterified form, orally, intramuscularly, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. (From Martindale, The Extra Pharmacopoeia, 30th ed, p739). triamcinolone : A C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections. | 1.93 | 1 | 0 | 11beta-hydroxy steroid; 16alpha-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid hormone; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone | anti-allergic agent; anti-inflammatory drug |
| 8-bromo cyclic adenosine monophosphate 8-Bromo Cyclic Adenosine Monophosphate: A long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase.. 8-Br-cAMP : A 3',5'-cyclic purine nucleotide that is 3',5'-cyclic AMP bearing an additional bromo substituent at position 8 on the adenine ring. An activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase. | 1.96 | 1 | 0 | 3',5'-cyclic purine nucleotide; adenyl ribonucleotide; organobromine compound | antidepressant; protein kinase agonist |
| etoposide [no description available] | 2.68 | 3 | 0 | beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound | antineoplastic agent; DNA synthesis inhibitor |
| colforsin Colforsin: Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland. | 1.96 | 1 | 0 | acetate ester; cyclic ketone; labdane diterpenoid; organic heterotricyclic compound; tertiary alpha-hydroxy ketone; triol | adenylate cyclase agonist; anti-HIV agent; antihypertensive agent; plant metabolite; platelet aggregation inhibitor; protein kinase A agonist |
| pyrrolidine dithiocarbamate pyrrolidine dithiocarbamic acid: spelled pyrolidine in J Nutr 1979 reference; RN given refers to parent cpd. pyrrolidine dithiocarbamate : A member of the class of dithiocarbamic acids that is the N-dithiocarboxy derivative of pyrrolidine. | 2 | 1 | 0 | dithiocarbamic acids; pyrrolidines | anticonvulsant; antineoplastic agent; geroprotector; neuroprotective agent; NF-kappaB inhibitor; radical scavenger |
| nogalamycin Nogalamycin: An anthrocycline from a Streptomyces nogalater variant. It is a cytolytic antineoplastic that inhibits DNA-dependent RNA synthesis by binding to DNA.. nogalamycin : An anthracycline antibiotic isolated from Streptomyces nogalater. It is a DNA intercalator and exhibits anticancer properties. | 2.92 | 4 | 0 | ||
| leupeptins Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins. | 2.02 | 1 | 0 | ||
| puromycin [no description available] | 2.67 | 3 | 0 | puromycins | antiinfective agent; antimicrobial agent; antineoplastic agent; EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor; EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor; nucleoside antibiotic; protein synthesis inhibitor |
| dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) | 9.15 | 89 | 1 | actinomycin | mutagen |
| aphidicolin Aphidicolin: An antiviral antibiotic produced by Cephalosporium aphidicola and other fungi. It inhibits the growth of eukaryotic cells and certain animal viruses by selectively inhibiting the cellular replication of DNA polymerase II or the viral-induced DNA polymerases. The drug may be useful for controlling excessive cell proliferation in patients with cancer, psoriasis or other dermatitis with little or no adverse effect upon non-multiplying cells.. aphidicolin : A tetracyclic diterpenoid that has an tetradecahydro-8,11a-methanocyclohepta[a]naphthalene skeleton with two hydroxymethyl substituents at positions 4 and 9, two methyl substituents at positions 4 and 11b and two hydroxy substituents at positions 3 and 9. An antibiotic with antiviral and antimitotical properties. Aphidicolin is a reversible inhibitor of eukaryotic nuclear DNA replication. | 1.99 | 1 | 0 | tetracyclic diterpenoid | antimicrobial agent; antimitotic; antineoplastic agent; antiviral drug; apoptosis inducer; Aspergillus metabolite; DNA synthesis inhibitor; EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor; fungal metabolite |
| melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring. | 3.48 | 1 | 1 | L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound | alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent |
| benzyloxycarbonylleucyl-leucyl-leucine aldehyde benzyloxycarbonylleucyl-leucyl-leucine aldehyde: proteasome inhibitor. N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal : A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative. | 2.02 | 1 | 0 | amino aldehyde; carbamate ester; tripeptide | proteasome inhibitor |
| thiouracil Thiouracil: Occurs in seeds of Brassica and Crucifera species. Thiouracil has been used as antithyroid, coronary vasodilator, and in congestive heart failure although its use has been largely supplanted by other drugs. It is known to cause blood dyscrasias and suspected of terato- and carcinogenesis.. thiouracil : A nucleobase analogue that is uracil in which the oxo group at C-2 is replaced by a thioxo group. | 1.96 | 1 | 0 | nucleobase analogue; thiocarbonyl compound | antithyroid drug; metabolite |
| tamoxifen [no description available] | 2.94 | 1 | 0 | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator |
| nadp [no description available] | 1.93 | 1 | 0 | ||
| dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins. | 2.37 | 2 | 0 | prostaglandins E | human metabolite; mouse metabolite; oxytocic |
| genistein [no description available] | 2.4 | 2 | 0 | 7-hydroxyisoflavones | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor |
| nad NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety. | 1.93 | 1 | 0 | organophosphate oxoanion | cofactor; human metabolite; hydrogen acceptor; Saccharomyces cerevisiae metabolite |
| glucagon Glucagon: A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511). glucagon : A 29-amino acid peptide hormone consisting of His, Ser, Gln, Gly, Thr, Phe, Thr, Ser, Asp, Tyr, Ser, Lys, Tyr, Leu, Asp, Ser, Arg, Arg, Ala, Gln, Asp, Phe, Val, Gln, Trp, Leu, Met, Asn and Thr residues joined in sequence. | 1.98 | 1 | 0 | peptide hormone | |
| actinomycin c3 actinomycin C3: structure | 2.15 | 1 | 0 | ||
| novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus. | 2.4 | 2 | 0 | carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols | antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent |
| muramidase Muramidase: A basic enzyme that is present in saliva, tears, egg white, and many animal fluids. It functions as an antibacterial agent. The enzyme catalyzes the hydrolysis of 1,4-beta-linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin. EC 3.2.1.17. | 1.99 | 1 | 0 | ||
| metallothionein Metallothionein: A low-molecular-weight (approx. 10 kD) protein occurring in the cytoplasm of kidney cortex and liver. It is rich in cysteinyl residues and contains no aromatic amino acids. Metallothionein shows high affinity for bivalent heavy metals. | 1.98 | 1 | 0 |
| Condition | Indicated | Relationship Strength | Studies | Trials |
|---|---|---|---|---|
| Disease Exacerbation [description not available] | 0 | 3.48 | 1 | 1 |
| Malignant Melanoma [description not available] | 0 | 3.76 | 2 | 1 |
| Sarcoma, Epithelioid [description not available] | 0 | 3.76 | 2 | 1 |
| Cancer of Skin [description not available] | 0 | 3.48 | 1 | 1 |
| Merkel Cell Cancer [description not available] | 0 | 3.48 | 1 | 1 |
| Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) | 0 | 3.76 | 2 | 1 |
| Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. | 0 | 3.76 | 2 | 1 |
| Skin Neoplasms Tumors or cancer of the SKIN. | 0 | 3.48 | 1 | 1 |
| Carcinoma, Merkel Cell A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245) | 0 | 3.48 | 1 | 1 |
| Dermatophytoses [description not available] | 0 | 1.93 | 1 | 0 |
| Tinea Fungal infection of keratinized tissues such as hair, skin and nails. The main causative fungi include MICROSPORUM; TRICHOPHYTON; and EPIDERMOPHYTON. | 0 | 1.93 | 1 | 0 |
| Di Guglielmo Disease [description not available] | 0 | 2.05 | 1 | 0 |
| Germinoblastoma [description not available] | 0 | 2.64 | 3 | 0 |
| Benign Neoplasms [description not available] | 0 | 3.88 | 13 | 0 |
| Leukemia, Erythroblastic, Acute A myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. | 0 | 2.05 | 1 | 0 |
| Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. | 0 | 2.64 | 3 | 0 |
| Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply. | 0 | 2.05 | 1 | 0 |
| Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. | 0 | 3.88 | 13 | 0 |
| Experimental Neoplasms [description not available] | 0 | 3.03 | 5 | 0 |
| Granuloma, Hodgkin [description not available] | 0 | 4.18 | 18 | 0 |
| Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. | 0 | 4.18 | 18 | 0 |
| Besnier-Boeck Disease [description not available] | 0 | 2.84 | 4 | 0 |
| Sarcoidosis An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands. | 0 | 2.84 | 4 | 0 |
| Cancer of Lung [description not available] | 0 | 2.33 | 2 | 0 |
| Lung Neoplasms Tumors or cancer of the LUNG. | 0 | 2.33 | 2 | 0 |
| Blood Diseases [description not available] | 0 | 1.93 | 1 | 0 |
| Hematologic Diseases Disorders of the blood and blood forming tissues. | 0 | 1.93 | 1 | 0 |
| Anaphylactic Reaction [description not available] | 0 | 1.93 | 1 | 0 |
| Allergic Reaction [description not available] | 0 | 1.93 | 1 | 0 |
| Diseases of Immune System [description not available] | 0 | 1.93 | 1 | 0 |
| Anaphylaxis An acute hypersensitivity reaction due to exposure to a previously encountered ANTIGEN. The reaction may include rapidly progressing URTICARIA, respiratory distress, vascular collapse, systemic SHOCK, and death. | 0 | 1.93 | 1 | 0 |
| Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. | 0 | 1.93 | 1 | 0 |
| Immune System Diseases Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both. | 0 | 1.93 | 1 | 0 |
| Leucocythaemia [description not available] | 0 | 2.85 | 4 | 0 |
| Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) | 0 | 2.85 | 4 | 0 |
| Diffuse Mixed Small and Large Cell Lymphoma [description not available] | 0 | 2.62 | 3 | 0 |
| Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. | 0 | 2.62 | 3 | 0 |
| Cancer of Nasopharynx [description not available] | 0 | 1.93 | 1 | 0 |
| Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. | 0 | 1.93 | 1 | 0 |
| Kahler Disease [description not available] | 0 | 2.33 | 2 | 0 |
| Plasma Cell Tumor [description not available] | 0 | 1.93 | 1 | 0 |
| Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. | 0 | 2.33 | 2 | 0 |
| Plasmacytoma Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites. | 0 | 1.93 | 1 | 0 |
| Mycosis Fungoides A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected. | 0 | 2.33 | 2 | 0 |
| Granulocytic Leukemia, Chronic [description not available] | 0 | 1.93 | 1 | 0 |
| Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) | 0 | 1.93 | 1 | 0 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. | 0 | 1.93 | 1 | 0 |
| Orphan Diseases Rare diseases that have not been well studied. | 0 | 1.93 | 1 | 0 |
| Leukemia, Lymphocytic [description not available] | 0 | 2.34 | 2 | 0 |
| Diffuse Large B-Cell Lymphoma [description not available] | 0 | 1.93 | 1 | 0 |
| Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. | 0 | 2.34 | 2 | 0 |
| Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation. | 0 | 1.93 | 1 | 0 |
| EHS Tumor [description not available] | 0 | 1.93 | 1 | 0 |
| Reticulum Cell-Like Sarcoma, Yoshida [description not available] | 0 | 1.93 | 1 | 0 |
| Neuritis A general term indicating inflammation of a peripheral or cranial nerve. Clinical manifestation may include PAIN; PARESTHESIAS; PARESIS; or HYPESTHESIA. | 0 | 1.93 | 1 | 0 |
| Anemia, Hemolytic, Acquired [description not available] | 0 | 1.93 | 1 | 0 |
| Acquired Autoimmune Hemolytic Anemia [description not available] | 0 | 1.93 | 1 | 0 |
| Autoimmune Disease [description not available] | 0 | 1.93 | 1 | 0 |
| Thrombopenia [description not available] | 0 | 1.93 | 1 | 0 |
| Autoimmune Thrombocytopenia [description not available] | 0 | 1.93 | 1 | 0 |
| Anemia, Hemolytic A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES). | 0 | 1.93 | 1 | 0 |
| Anemia, Hemolytic, Autoimmune Acquired hemolytic anemia due to the presence of AUTOANTIBODIES which agglutinate or lyse the patient's own RED BLOOD CELLS. | 0 | 1.93 | 1 | 0 |
| Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. | 0 | 1.93 | 1 | 0 |
| Thrombocytopenia A subnormal level of BLOOD PLATELETS. | 0 | 1.93 | 1 | 0 |
| Purpura, Thrombocytopenic, Idiopathic Thrombocytopenia occurring in the absence of toxic exposure or a disease associated with decreased platelets. It is mediated by immune mechanisms, in most cases IMMUNOGLOBULIN G autoantibodies which attach to platelets and subsequently undergo destruction by macrophages. The disease is seen in acute (affecting children) and chronic (adult) forms. | 0 | 1.93 | 1 | 0 |
| Carcinoma, Anaplastic [description not available] | 0 | 1.93 | 1 | 0 |
| Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms. | 0 | 1.93 | 1 | 0 |
| Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer. | 0 | 1.93 | 1 | 0 |
| Cadaver A dead body, usually a human body. | 0 | 1.94 | 1 | 0 |
| Blood Poisoning [description not available] | 0 | 1.94 | 1 | 0 |
| Histoplasma capsulatum Infection [description not available] | 0 | 1.94 | 1 | 0 |
| Chronic Kidney Failure [description not available] | 0 | 1.94 | 1 | 0 |
| Histoplasmosis Infection resulting from exposure to the fungus HISTOPLASMA. It is worldwide in distribution and particularly common in the central and eastern states, especially areas around the Ohio and Mississippi River valleys. | 0 | 1.94 | 1 | 0 |
| Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. | 0 | 1.94 | 1 | 0 |
| Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK. | 0 | 1.94 | 1 | 0 |
| Angiosarcoma [description not available] | 0 | 1.94 | 1 | 0 |
| Cancer of Kidney [description not available] | 0 | 1.94 | 1 | 0 |
| Cancer of Pancreas [description not available] | 0 | 1.94 | 1 | 0 |
| Cancer of Stomach [description not available] | 0 | 1.94 | 1 | 0 |
| Mesonephroma A rare tumor of the female genital tract, most often the ovary, formerly considered to be derived from mesonephric rests. Two varieties are recognized: (1) clear cell carcinoma, so called because of its histologic resemblance to renal cell carcinoma, and now considered to be of muellerian duct derivation and (2) an embryonal tumor (called also ENDODERMAL SINUS TUMOR and yolk sac tumor), occurring chiefly in children. The latter variety may also arise in the testis. (Dorland, 27th ed) | 0 | 1.94 | 1 | 0 |
| Hemangiosarcoma A rare malignant neoplasm characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood vessels and lining irregular blood-filled or lumpy spaces. (Stedman, 25th ed) | 0 | 1.94 | 1 | 0 |
| Kidney Neoplasms Tumors or cancers of the KIDNEY. | 0 | 1.94 | 1 | 0 |
| Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). | 0 | 1.94 | 1 | 0 |
| Stomach Neoplasms Tumors or cancer of the STOMACH. | 0 | 1.94 | 1 | 0 |
| Local Neoplasm Recurrence [description not available] | 0 | 2.02 | 1 | 0 |
| Rhabdomyosarcoma A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9) | 0 | 2.02 | 1 | 0 |
| Gestational Trophoblastic Neoplasia Gestational Trophoblastic diseases that are malignant. It does not include HYDATIDIFORM MOLE. However, there is a minority of authors that consider the term gestational trophoblastic neoplasia synonymous with gestational trophoblastic disease. | 0 | 2.93 | 1 | 0 |
| Gestational Trophoblastic Disease A group of diseases arising from pregnancy that are commonly associated with hyperplasia of trophoblasts (TROPHOBLAST) and markedly elevated human CHORIONIC GONADOTROPIN. They include HYDATIDIFORM MOLE, invasive mole (HYDATIDIFORM MOLE, INVASIVE), placental-site trophoblastic tumor (TROPHOBLASTIC TUMOR, PLACENTAL SITE), and CHORIOCARCINOMA. These neoplasms have varying propensities for invasion and spread. | 0 | 2.93 | 1 | 0 |
| Hepatocellular Carcinoma [description not available] | 0 | 2.02 | 1 | 0 |
| Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. | 0 | 2.02 | 1 | 0 |
| Cancer of Ovary [description not available] | 0 | 2.94 | 1 | 0 |
| Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. | 0 | 2.94 | 1 | 0 |
| Gastric Ulcer [description not available] | 0 | 1.96 | 1 | 0 |
| Stomach Ulcer Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS). | 0 | 1.96 | 1 | 0 |
| Ewing Sarcoma [description not available] | 0 | 1.98 | 1 | 0 |
| Sarcoma, Ewing A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females. | 0 | 1.98 | 1 | 0 |
| Thoracic Neoplasms New abnormal growth of tissue in the THORAX. | 0 | 1.98 | 1 | 0 |
| Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. | 0 | 2 | 1 | 0 |